Kura Oncology reported a Q2 2024 operating loss with no reported revenue, consistent with a clinical-stage biotechnology company advancing a broad menin inhibitor program. Key near-term catalysts include topline data from KOMET-001 in NPM1-mutant relapsed/refractory AML slated for early 2025 and continued enrollment expansion in KOMET-007, with over 100 patients dosed across dose cohorts and genotypes, including progression toward 600 mg expansion arms. The company also advanced non-AML programs, including GIST (IND clearance for ziftomenib + imatinib) and preclinical data supporting diabetes indications with a next-generation candidate slated for nomination in early 2025. Importantly, Kura entered 2024 with a substantial liquidity position ($491.5 million in cash, cash equivalents, and short-term investments) and guided that this buffer is sufficient to fund the operating plan into 2027, providing substantial runway for multiple phase 2/early phase 3 readouts and pivotal planning alongside ongoing collaborations (e.g., KO-2806 and tipifarnib programs). While the near-term financials reflect a typical pre-commercial burn (R&D of $39.7M and G&A of $16.7M in Q2 2024), investors should weigh the magnitude of upcoming data readouts, regulatory interactions, and the potential addressable markets across AML subtypes, GIST, and diabetes against execution risk and the evolving competitive landscape in menin inhibitors and combination therapies.